Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials
Pharmatech, Inc., a Research Management Organization (RMO), has contracted with five leading pharmaceutical companies to provide research and site management services for their clinical trials using the Just-in-Time (JIT) enrollment strategy.
Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials
New JIT Enrollment Program Speeds Oncology Patient Accrual
DENVER, July 24, 2008 /PRNewswire via COMTEX/ -- Pharmatech, Inc., a Research Management Organization (RMO), has contracted with five leading pharmaceutical companies to provide research and site management services for their clinical trials using the Just-in-Time (JIT) enrollment strategy. The new trials include the following disease indications: follicular Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Metastatic Sarcoma, Chronic Myelogenous Leukemia, and Non-Small Cell Lung Cancer (NSCLC).
Pharmatech will manage the trials using its innovative JIT approach. This streamlined approach was created to increase enrollment in oncology clinical trials. This patient first initiative allows for identification of cancer patients through basic standard of care procedures, so the site opens only if the patient qualifies for the study. Patient enrollment increases because a protocol is rolled out to a large number of qualified Research Network sites with minimal expense of time and capital for both the sites and sponsors.
The new oncology clinical trials are targeted to achieve enrollment of over 500 cancer patients with the participation of approximately 165 Pharmatech Research Network sites. Matthew Wiener, Pharmatech CEO, states that "The recent activity in new business has been a true testament to the acceptance of the Just-In-Time enrollment strategy. Study sponsors and sites have praised the new enrollment methodology, as cancer patients are treated in a more efficient manner and sponsors see their trials completed in a shorter time frame."
About Pharmatech, Inc.:
Pharmatech, headquartered in Denver, Colorado, is a Research Management Organization (RMO) dedicated to the highest quality of clinical research. Pharmatech provides services of a Site Management Organization (SMO) and a Contract Research Organization (CRO) with a focus in oncology clinical trials. Through an organized research network, the Company focuses on the development and utilization of therapeutic products among sponsors, investigators, and patients. For more information about Pharmatech, please visit http://www.pharmatech.com.
SOURCE Pharmatech, Inc.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
